Annual Accounts Receivable
N/A
01 July 2024
Summary:
BriaCell Therapeutics annual accounts receivable is not available.BCTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
N/A
01 July 2024
Summary:
BriaCell Therapeutics quarterly accounts receivable is not available.BCTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
BCTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time |
BriaCell Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Apr 2024 | - | $15.20 K(-49.5%) |
| Jan 2024 | - | $30.10 K(+40.7%) |
| Oct 2023 | - | $21.40 K(+43.6%) |
| Apr 2023 | - | $14.90 K(+67.4%) |
| Jan 2023 | - | $8900.00(-70.0%) |
| Oct 2022 | - | $29.70 K(+23.2%) |
| July 2022 | $24.10 K(+91.3%) | $24.10 K(+66.2%) |
| Apr 2022 | - | $14.50 K(-46.7%) |
| Jan 2022 | - | $27.20 K(+40.9%) |
| Oct 2021 | - | $19.30 K(+53.2%) |
| July 2021 | $12.60 K(-44.0%) | $12.60 K(-20.3%) |
| Apr 2021 | - | $15.80 K(+243.5%) |
| Jan 2021 | - | $4600.00(-24.6%) |
| Oct 2020 | - | $6100.00(-72.9%) |
| July 2020 | $22.50 K(+703.6%) | $22.50 K(+7400.0%) |
| Apr 2020 | - | $300.00(+50.0%) |
| Jan 2020 | - | $200.00(-93.8%) |
| Oct 2019 | - | $3200.00(+14.3%) |
| July 2019 | $2800.00(-80.8%) | $2800.00(-44.0%) |
| Apr 2019 | - | $5000.00(-67.1%) |
| Jan 2019 | - | $15.20 K(-35.9%) |
| Oct 2018 | - | $23.70 K(+62.3%) |
| July 2018 | $14.60 K(+160.7%) | $14.60 K(-21.5%) |
| Apr 2018 | - | $18.60 K(+564.3%) |
| Jan 2018 | - | $2800.00(+64.7%) |
| Oct 2017 | - | $1700.00(-69.6%) |
| July 2017 | $5600.00 | $5600.00(+43.6%) |
| Apr 2017 | - | $3900.00(-68.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jan 2017 | - | $12.40 K(+47.6%) |
| Oct 2016 | - | $8400.00(+211.1%) |
| July 2016 | $2700.00(-90.1%) | $2700.00(-75.0%) |
| Apr 2016 | - | $10.80 K(+31.7%) |
| Jan 2016 | - | $8200.00(-30.5%) |
| Oct 2015 | - | $11.80 K(-56.6%) |
| July 2015 | $27.20 K(>+9900.0%) | $27.20 K(+19.8%) |
| Apr 2015 | - | $22.70 K(+69.4%) |
| Jan 2015 | - | $13.40 K(+139.3%) |
| Oct 2014 | - | $5600.00(>+9900.0%) |
| July 2014 | $0.00(-100.0%) | $0.00(-100.0%) |
| Apr 2014 | - | $12.00 K(+76.5%) |
| Jan 2014 | - | $6800.00(-56.1%) |
| Oct 2013 | - | $15.50 K(+49.0%) |
| July 2013 | $10.40 K(-82.0%) | $10.40 K(+44.4%) |
| Apr 2013 | - | $7200.00(-42.9%) |
| Jan 2013 | - | $12.60 K(-78.2%) |
| July 2012 | $57.80 K(+950.9%) | $57.80 K(-50.9%) |
| Apr 2012 | - | $117.80 K(+25.1%) |
| Jan 2012 | - | $94.20 K(-50.4%) |
| Oct 2011 | - | $189.80 K(+236.5%) |
| Apr 2011 | - | $56.40 K(+113.6%) |
| Jan 2011 | - | $26.40 K(+97.0%) |
| Oct 2010 | - | $13.40 K(+458.3%) |
| Oct 2008 | - | $2400.00(-56.4%) |
| July 2008 | $5500.00 | $5500.00(+358.3%) |
| Apr 2008 | - | $1200.00(-77.4%) |
| Apr 2007 | - | $5300.00(+26.2%) |
| Jan 2007 | - | $4200.00 |
FAQ
- What is the all time high annual accounts receivable for BriaCell Therapeutics?
- What is the all time high quarterly accounts receivable for BriaCell Therapeutics?
What is the all time high annual accounts receivable for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual accounts receivable is $57.80 K
What is the all time high quarterly accounts receivable for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly accounts receivable is $189.80 K